Bayer/Onyx's Nexavar fails Phase III melanoma trial
28 April 2009
Malini Guha
Bayer/
Onyx Pharmaceutical's multi-targeted kidney and liver cancer drug Nexavar (sorafenib) has failed a first-line Phase III trial in advanced melanoma in combination with chemotherapy, which could spell the end of the drug for this difficult-to-treat disease.
The ECOG 2603 trial, which enrolled...
Please Login to read the full article.
28 April 2009
Malini Guha
The ECOG 2603 trial, which enrolled...
Please Login to read the full article.
RELATED CONTENT
NEWS
- FDA reviewers question efficacy of Pfizer's kidney cancer drug ahead of ODAC
- Infinity minus one: shares plummet as spiky saridegib fails in pancreatic cancer
- Ben Venue manufacturing difficulties spell delays for Clavis' Phase III CLAVELA trial
- Transgene puts its best foot forward at first R&D day
FEATURES
Other Informa Features
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
